# Circle Pharma

> Clinical-stage biopharmaceutical company in South San Francisco, California, developing cell-permeable, orally bioavailable macrocycle therapies for cancer using its proprietary MXMO structure-based design platform. Lead program CID-078, a first-in-class oral cyclin A/B RxL inhibitor, is in Phase 1 for advanced solid tumors. Founded 2013.

Generated: 2026-08-01
Method: generated (from apis.yml + repo artifacts; /llms.txt returns 404 on circlepharma.com)
Source: https://circlepharma.com/

Circle Pharma runs no developer program and markets no API. The one machine-readable surface the
company exposes is the anonymously readable WordPress REST content API behind circlepharma.com,
published at https://circlepharma.com/wp-json/. Everything in the "APIs" and "Specs" sections below
describes that surface. The OpenAPI in this repo was derived by API Evangelist from the site's own
published route index — it is not a Circle Pharma specification.

## Company

- [Home](https://circlepharma.com/): Company overview and MXMO platform positioning
- [About Us](https://circlepharma.com/about-us): Founding (2013), leadership, board, scientific advisory board
- [Our Science](https://circlepharma.com/our-science): Macrocycle chemistry and the MXMO discovery platform
- [Our Pipeline](https://circlepharma.com/our-pipeline): CID-078 (cyclin A/B RxL, Phase 1), preclinical cyclin D1 RxL, undisclosed cyclin programs partnered with Boehringer Ingelheim
- [Clinical Trials](https://circlepharma.com/clinical-trials): Trial information and Expanded Access Policy
- [Investors](https://circlepharma.com/investors): Investor information ($90M Series D led by The Column Group, 2024)
- [Work With Us](https://circlepharma.com/work-with-us): Careers
- [Contact Us](https://circlepharma.com/contact-us): 169 Harbor Way, South San Francisco, CA 94080 — info@circlepharma.com — 650-825-4099

## News

- [What's New](https://circlepharma.com/whats-new): Combined news stream
- [Press Releases](https://circlepharma.com/press-releases): 52 items as of 2026-08-01
- [Publications](https://circlepharma.com/publications): 46 items
- [In the News](https://circlepharma.com/in-the-news): 8 items
- [Upcoming Events](https://circlepharma.com/upcoming-events): Conference and investor appearances
- [RSS feed](https://circlepharma.com/feed/): RSS 2.0

## APIs

- [Circle Pharma Content API](https://circlepharma.com/wp-json/): WordPress REST API (wp/v2), anonymous read, JSON. Base URL https://circlepharma.com/wp-json
- [Route index](https://circlepharma.com/wp-json/): 349 registered routes across 18 namespaces; the discovery document this profile is derived from
- [WordPress REST API handbook](https://developer.wordpress.org/rest-api/): Upstream documentation for the wp/v2 contract

Public read collections (all verified HTTP 200 without credentials on 2026-08-01):

- `GET /wp-json/wp/v2/posts` — press releases, publications, in-the-news (107 records)
- `GET /wp-json/wp/v2/pages` — pipeline, science, clinical-trial and corporate pages (20)
- `GET /wp-json/wp/v2/team` — leadership, board, SAB and staff (61)
- `GET /wp-json/wp/v2/member_type` — team segmentation taxonomy (4 terms)
- `GET /wp-json/wp/v2/all_events` — events calendar (5)
- `GET /wp-json/wp/v2/event_type` — event taxonomy (2 terms)
- `GET /wp-json/wp/v2/categories` — post categories (4 terms)
- `GET /wp-json/wp/v2/media` — images and documents (323)
- `GET /wp-json/wp/v2/search?search=` — cross-content search
- `GET /wp-json/wp/v2/types`, `/taxonomies`, `/statuses` — schema discovery

Not available anonymously: `/wp/v2/users` and `/wp/v2/settings` return 401.

## Specs

- [OpenAPI 3.1 (derived)](openapi/circle-pharma-content-openapi.yml): 26 read operations over the content surface
- [Overlay](overlays/circle-pharma-content-overlay.yaml): API Evangelist annotations, record counts and usage notes
- [Data model](data-model/circle-pharma-data-model.yml): Entity graph — posts, pages, team, events, taxonomies, media and their relationships
- [Conventions](conventions/circle-pharma-conventions.yml): Pagination, sparse fieldsets, `_embed`, caching, error envelope
- [Error catalog](errors/circle-pharma-problem-types.yml): Live-probed WordPress error codes (not RFC 9457)
- [Authentication](authentication/circle-pharma-authentication.yml): None for read; Application Passwords (HTTP Basic) for the out-of-scope write routes
- [Lifecycle](lifecycle/circle-pharma-lifecycle.yml): Namespace versioning; no deprecation policy, SLA, status page or API changelog
- [Conformance](conformance/circle-pharma-conformance.yml): Standards observed and not observed
- [Domain security](security/circle-pharma-domain-security.yml): TLS 1.3; no HSTS, no DNSSEC, no CAA; SPF present, DMARC p=none
- [Well-known](well-known/circle-pharma-well-known.yml): Every RFC 8615 path probed — all 404

## Agent notes

- The public contract is read-only. There is no write, no idempotency key, no webhook, no event stream
  and no MCP server. Do not assume any of these exist.
- Use `_fields` to trim responses and `_embed` to inline featured media and taxonomy terms.
- Paginate with `page`/`per_page` (max 100) and read `X-WP-Total` / `X-WP-TotalPages`; paging past the
  last page returns 400 `rest_post_invalid_page_number`.
- `title`, `content` and `excerpt` are objects with a `rendered` HTML string, not plain strings.
- Errors are `{"code","message","data":{"status"}}` — WordPress-native, not `application/problem+json`.
- No rate-limit headers are published. Cache for at least 10 minutes (the origin's own `max-age`) and
  honor the `Crawl-delay: 10` in robots.txt.
- `/wp/v2/comments` is anonymously readable but is largely inbound spam; it is not Circle Pharma content.
- For clinical or medical information, the authoritative source is the company's own pages and
  ClinicalTrials.gov, not this content API.